GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects
Major depression affects about 10 percent of the adult population and is the second leading cause of disability in U.S. adults, according to the World Health Organization. Despite the availability of several different classes of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), 30 to 40 percent of adults are unresponsive to these medications. Moreover, SSRIs typically take weeks to work, which increases the risk for suicide.
Enter NMDA (N-methyl-D-aspartate) receptor modulators. In the 1970s, researchers linked the receptors to learning and memory. Biotech and pharmaceutical companies in the 1980s attempted to apply chemical blockers to these receptors as a means to prevent stroke. But blocking these receptors led to the opposite effect—–the rise of cardiovascular disease. Research in the field dampened until a glutamate receptor antagonist already approved for anesthesia, and known on the streets as “Special K”, ketamine, made headlines in the early 2000s. Human clinical studies demonstrated that ketamine can ward off major and bipolar depressive symptoms within 2 hours of administration and last for several days. Ketamine is fraught with serious side effects including excessive sleepiness, hallucinations, and substance abuse behavior.
“Ketamine lit the field back up,“ said Joseph Moskal, Ph.D., a molecular neurobiologist at Northwestern University and senior study author. “Our drug, GLYX-13, is very different. It does not block the receptor ion channel, which may account for why it doesn’t have the same side effects.”
Moskal’s journey with GLYX-13 came about from his earlier days as a Senior Staff Fellow in NIMH’s Intramural Research Program. While at NIMH, he created specific molecules, monoclonal antibodies, to use as new probes to understand pathways of learning and memory. Some of the antibodies he created were for NMDA receptors. When he moved to Northwestern University, Moskal converted the antibodies to small protein molecules. Comprised of only four amino acids, GLYX-13 is one of these molecules.
Previous electrophysiological and conditioning studies had suggested that GLYX-13, unlike ketamine, enhanced memory and learning in rats, particularly in the brain’s memory hub or hippocampus. GLYX-13 also produced analgesic effects. Using several rat behavioral and molecular experiments, Moskal’s research team tested four compounds: GLYX-13, an inactive, “scrambled” version of GLYX-13 that had its amino acids rearranged, ketamine, and the SSRI fluoxetine.
Results of the Study
GLYX-13 and ketamine produced rapid acting (1 hour) and long-lasting (24 hour) antidepressant-like effects in the rats. Fluoxetine, an SSRI that typically takes from 2–4 weeks to show efficacy in humans, did not produce a rapid antidepressant effect in this study. As expected, the scrambled GLYX-13 showed no antidepressant-like effects at all. The researchers observed none of the aforementioned side effects of ketamine in the GLYX-13–treated rats.
Protein studies indicated an increase in the hippocampus of the NMDA receptor NR2B and a receptor for the chemical messenger glutamate called AMPA. Electrophysiology studies in this brain region showed that GLYX-13 and ketamine promoted long-lasting signal transmission in neurons, known as long-term potentiation/synaptic plasticity. This phenomenon is essential in learning and memory. The researchers propose how GLYX-13 works: GLYX-13 triggers NR2B receptor activation that leads to intracellular calcium influx and the expression of AMPA, which then is responsible for increased communication between neurons.
These results are consistent with data from a recent Phase 2 clinical trial, in which a single administration of GLYX-13 produced statistically significant reductions in depression scores in patients who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of 7 days. After a single dose of GLYX-13, the drug’s antidepressant efficacy nearly doubled that seen with most conventional antidepressants after 4–6 weeks of dosing. GLYX-13 was well tolerated and it did not produce any of the schizophrenia-like effects associated with other NMDA receptor modulating agents.
The Latest Bing News on:
- Biogen bets on depression drug in $1.5 billion deal with Sage Therapeuticson November 27, 2020 at 3:31 pm
Biogen Inc will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders, the ...
- Biogen makes risky bet on trial depression drugon November 27, 2020 at 2:58 pm
The $1.5 billion deal with Sage Therapeutics will try to salvage an oral treatment that had a disappointing clinical trial ...
- Biogen, Sage Therapeutics enter $1.5 billion deal to develop, sell depression drugon November 27, 2020 at 9:49 am
Biogen Inc has entered into an agreement with Sage Therapeutics to jointly develop and sell a treatment for major depressive disorder, the two companies said on Friday.
- Biogen teams up with Sage Therapeutics to develop therapies in depressionon November 27, 2020 at 9:45 am
Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive ...
- Sage to Get $1.53 Billion From Biogen for Depression Drug Developmenton November 27, 2020 at 9:42 am
The companies will develop Sage’s zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders.
- In major bet, Biogen pays $1.5 billion for rights to a once-failed treatment for depressionon November 27, 2020 at 6:11 am
The company will retain the commercial rights to a Sage Therapeutics’ drug that disappointed in its last major clinical trial.
- Seasonal depression could be worse than ever this yearon November 25, 2020 at 2:18 pm
How to avoid seasonal depression caused by daylight saving end Over half of American adults say their mental health has suffered due to the coronavirus pandemic, and as the weather ...
- Depression Screening Market Report Gives Industry Size, Growth, Production, Types, Applications, Growing Rapidly with Recent Trends 2020 to 2025on November 25, 2020 at 12:49 am
Depression Screening Market ” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Depression ...
- Anxiety, Depression Symptoms Surged In US Due To Coronavirus Pandemic, Analysis Revealson November 23, 2020 at 9:48 pm
The results of a survey conducted by the Census Bureau revealed that symptoms of depression and anxiety have worsened among Americans amid the COVID-19 pandemic. Helplines across the country have also ...
- Hopkins study shows 'magic mushrooms' may be effective in treating major depressionon November 23, 2020 at 4:13 am
Could magic mushrooms help the more than 300 million people worldwide who have experienced major depression? According to this Hopkins study, potentially. #healthcare #Baltimore #health #medicine ...
The Latest Google Headlines on:
The Latest Bing News on:
Fix the internet
- Consumer Reports tests WiFi range extenders to fix spotty internet connectionon November 27, 2020 at 5:57 pm
The experts at Consumer Reports recently tested several WiFi range extenders to potentially fix a spotty internet connection or dead zones.
- Amazon's $599 router system isn't cheap, but it helps fix your bad Wi-Fion November 27, 2020 at 4:44 pm
You might want to try mesh networking if you know you pay for fast internet but feel like your home Wi-Fi is slow in some rooms.
- NHL jerseys: An honest review of every team's current uniforms, from the classics to teams in need of a changeon November 27, 2020 at 2:09 pm
Following the rankings and grades for those jerseys, I figured it would be an appropriate time to do a general check-in with the state of every team's uniforms while proposing some ways to make them ...
- Drupal issues emergency fix for critical bug with known exploitson November 27, 2020 at 8:31 am
Drupal has released emergency security updates to address a critical vulnerability with known exploits that could allow for arbitrary PHP code execution on some CMS versions.
- Autodoorstep - Get High Quality Professional Cleaning, Maid,Repair & Home Services In Dubaion November 26, 2020 at 4:19 pm
Therefore to help the residents of Dubai and to save them from the hassles of cleaning and managing things in their homes, office, and workplaces the company is offering various kinds of cleaning ...
- Alibaba CEO says regulations for internet firms ‘necessary’on November 23, 2020 at 11:00 am
HONG KONG (AP) — The chairman and CEO of e-commerce giant Alibaba Group praised Chinese regulators Monday in a possible attempt to repair ties after the stock market debut of its former ...
- The pandemic uncovered south Phoenix's digital divide. Here's how the city wants to forge a permanent fixon November 20, 2020 at 8:43 am
Imelda Hartley's children struggled with remote school in a home with slow internet. Phoenix provided a stopgap as it looks to fix the digital divide.
- Sony has a fix for the PS5 'Queued for Download' bugon November 20, 2020 at 6:59 am
There's now a fix for a particularly inconvenient bug that's been happening on the PS5. According to the Ask PlayStation Twitter, players now have the ability to help get rid of a bug that resulted in ...
- This messaging app uploads every file you send to the internet, which is badon November 19, 2020 at 1:23 pm
Messaging app Go SMS Pro, which has over 100 million installs from the Google Play store, has a massive security flaw that potentially allows people to access the sensitive content you’ve sent using ...
- Working from home with weak internet? There's a device to fix thaton November 19, 2020 at 1:04 am
Doing school, work or relaxing at home can put a strain on your internet, but mesh devices can boost your Wi-Fi. And 2020 brings a new twist: Wi-Fi 6.